Advances in medical technology and medicine have opened new avenues to treat injuries and diseases in an unconventional way that can restore patients’ mobility and durably relieve pain, without long and complex procedures. As such, ground-breaking medical care like regenerative medicine continues to gain steam and evolve over the last few decades to help medical professionals repair and rejuvenate damaged and injured body tissues.
Articular cartilage is a highly specialised tissue found on the extremities of the bones inside the synovial joints, such as the knee, hip, ankle and others. Its function is to allow for effective human movement by providing low-friction surfaces that can glide effortlessly one over another. However, due to its avascular nature, regenerating damaged articular cartilage in synovial joints has been challenging, and attempts made by first- and second-generation regenerative therapies had a very limited impact. Industry expert, Hicham Youssoufi Alaoui recalls that the human body’s healing systems do not promote regeneration of damaged cartilage, thereby making it imperative for any solution to be effective to provide the right environment for the body’s own cells. “Most treatments for cartilage defects are cantered towards symptomatic relief, such as pain management. Very few have come up with solutions that efficiently restore functionality of the joints once injured,” stresses Mr. Alaoui. CeiROx Life Sciences, currently operating as BioTissue, was born to change this narrative.
CeiROx Life Sciences offers robust solutions – the 3rd generation BioSeed®-C and the 4th generation chondrotissue® – that allow for the regeneration of high-end, high-quality cartilage in synovial joints in a sustainable manner. “We created a new paradigm of regenerative medicine by which we can enhance and bring the human body’s innate healing system to regenerate the once damaged cartilage tissue,” exclaims Mr. Alaoui, CEO, CeiROx Life Sciences. He further adds that the standard techniques to treat a cartilage injury – either due to traumatic or age-related reasons – include symptomatic treatments, such as pain medicine, small surgical procedures with limited efficacy, such as microfracture, and artificial joint replacement surgery among others. While these solutions might provide temporary relief and allow for day-to-day activities of the patients, they do not help to promote the full functionality of the joints. To break the monotony of such imperfect treatment procedures, CeiROx Life Sciences is combining more than two decades of research and development to build unique technology solutions in this field.
BioSeed®-C is CeiROx Life Science’s 3rd generation solution. Its landmark achievement consists in its autologous 3-dimensional chondrocyte graft. The latter was key to successfully repair cartilage defects in the knee by replacing the missing tissue and restoring its original function. The company’s solutions take human cells as the force behind the regenerative process. BioSeed®-C applies the principle of tissue engineering and is made of the patient’s own cells harvested from a tissue biopsy and then cultured in a laboratory. Once a sufficient cell number has been obtained, they are applied to a proprietary 3D-resorbable scaffold to form the finished cartilage implant, which is then reimplanted into the cartilage defect by minimally invasive procedures. Unlike other cell-based implants, in the form of liquid cell suspensions or cells suspended in a gel-like structure such as collagen – representing 1st and 2nd generation solutions respectively – that fail to provide good conditions for re-growing of high-quality cartilage, CeiRox Life Sciences developed a novel cutting edge three-dimensional mechanically stable matrix that provides an optimal environment for the cells to regenerate and form high-quality cartilage tissue.
We created a new paradigm of regenerative medicine by which we can enhance and bring the human body’s innate healing system to regenerate the once damaged cartilage tissues
Owing to its superior biomechanical stability and regenerative properties, this highly sustainable solution offers 12-year post-operation follow-up data showing durable significant clinical improvement.
CeiROx Life Sciences took its own achievements one level further by developing its 4th generation solution: chondrotissue®. The latter is a one-step procedure for the treatment of cartilage defects in synovial joints. chondrotissue® builds on the 3rd generation solution BioSeed-C premises and optimized its techniques with premium technologies to bring out-of-the-box results. What makes chondrotissue® a cutting edge solution is its smart scaffold property that allows patients to skip the biopsy surgery and lengthy and expensive cell culture processes in the lab. A key advantage of chondrotissue® lies in the fact that the locally recruited human cells can be directly absorbed into the scaffold, which provides them optimal environmental conditions and allows them to grow and regenerate where it is needed. A one-step, CE marked, cell-free implant, chondrotissue® is used to treat articular cartilage damage not only in the knee but also in the ankle, the hip and other synovial joints. chondrotissue® also serves a wide variety of patients–from the young to the older population, and it treats different defect sizes. Besides, as opposed to the porcine-based gel membranes, CeiRox Life Sciences’ chondrotissue® is synthetic and fits in different ethical systems. In fact, due to its efficient shape memory, the state-of-the-art solution can be applied arthroscopically, diminishing the need for open surgery.
Clearly, the uniqueness of CeiROx Life Sciences stems from its rich expertise in the field of tissue engineering and regenerative medicine. CeiROx Life Sciences began its journey by developing competent solutions for skin regeneration, bone regeneration, and several other applications in the human body. As years rolled by, the company infused its deep-seated knowledge to manufacture products that help clients navigate the complex realm of pathological disorders. Mr. Alaoui mentions that CeiROx Life Sciences continually innovates its products to make the life of patients better and to offer user-friendly solutions to healthcare professionals. In fact, to further bolster its offerings around solutions that repair synovial joints, the company took a leap from its third-generation regenerative cartilage solution BioSeed®-C to a highly optimised fourth-generation chondrotissue®.
Considering the plethora of benefits these solutions bring to the table, CeiRox Life Sciences has emerged as the one-stop-shop for patients and hospitals alike. To further illustrate the efficacy of its products, Mr. Alaoui cites a case study of a female who was a victim of the terrorist attack in Manchester. With severe injuries in her ankle, the terrorist-attack survivor was at risk of needing an amputation. However, CeiROx Life Sciences used its proficient solution chondrotissue® for cartilage regeneration, which was combined on work on the bone defects and successfully restored the articular cartilage of the joint, thereby saving the patient’s ankle from amputation. This also highlights that unlike other market products that require a healthy cartilage shoulder around the defect to achieve desirable results, CeiROx Life Sciences can trigger the process of regeneration sustainably without needing healthy tissue around.
With innovation at its core, CeiROx Life Sciences aims to continue creating wavelets across the healthcare landscape in the domain of regenerative medicine treatments. Focusing on the lab and research/scientific developments for a long time, the company now plans to focus on revitalising the business model by democratising access to its products. Through its user-friendly, cutting-edge solutions, the company looks forward to expanding its geographical reach beyond Europe and is working with the FDA to enter the US market soon. “We are building all the blocks and pillars needed for the successful growth of the product and the company. We look forward to redefine orthopaedics across the world,” concludes Mr. Alaoui.